Buparlisib was heavily investigated in breast cancers with the thought that targeting both PI3K and estrogen receptors can prevent estrogen receptor (ER) activation in endocrine therapy-resistant tumors and overcome mTOR feedback activation [106,107]. Here, PIK3CD is linked to breast carcinoma.